Dihydroergotamine mesylate Catalog No.:M19056-C Smiles: C/C(=N\OCC1C=CC(C2CCCCC2)=C(C=1)C(F)(F)F)/C1C=C(CC)C(CN2CC(C2)C(O)=O)=CC=1

Smiles: C/C(=N\OCC1C=CC(C2CCCCC2)=C(C=1)C(F)(F)F)/C1C=C(CC)C(CN2CC(C2)C(O)=O)=CC=1

Astrid S Clarke

Smiles: CC1=CC(=CC=C1OC)S(=O)(=O)N1CCCCC1

InChi: InChI=1S/C29H32Cl2N4O5/c30-22-14-21(15-23(31)16-22)24(17-28(37)38)35-29(39)25(19-40-18-20-8-2-1-3-9-20)34-27(36)11-5-7-13-33-26-10-4-6-12-32-26/h1-4

intracranially implanted with glioma xenografts

Dihydroergotamine mesylate Catalog No.:M19056-C Smiles: C/C(=N\OCC1C=CC(C2CCCCC2)=C(C=1)C(F)(F)F)/C1C=C(CC)C(CN2CC(C2)C(O)=O)=CC=1Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines. Target: 5 HT ReceptorsDihydroergotamine is not as effective as sumatriptan or phenothiazines as a single agent for treatment of acute migraine headache; however, when administered with an antiemetic, dihydroergotamine appears to be as effective as opiates, ketorolac, or valproate. Given its nonnarcotic properties, parenteral dihydroergotamine combined with an antiemetic should be